Closing
Do SGLT2 inhibitors improve quality of life & behaviour versus placebo?
Mostly studied in type 2 & unspecified diabetes.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Unlikely. So far, the results disagree.
NoUnsureYes
- Belief
- 0.00 (range 0.00–0.55)
- Trials for
- 0
- Trials against
- 4
- Inconclusive
- 2
Already under way
- The Effects of SGLT2 Inhibition on Vascular Health and Physical Function in Veterans With CKDNCT07060417 · not yet recruiting · started 2026
- Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type 2 Diabetes MellitusNCT07441187 · not yet recruiting · started 2026
- Empagliflozin as an Adjunctive Strategy for Treating Bipolar Depression in Patients With Insulin Resistance: A Proof-of-Concept Study (EMPA-BD)NCT07472920 · not yet recruiting · started 2026
- A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2…NCT07547878 · not yet recruiting · started 2026
- Effects of SGLT2 Inhibitors on Coronary Atherosclerosis Progression in Diabetes Mediated by Perivascular Adipose Tissue: The SCOPE TrialNCT07614230 · recruiting · started 2026
The evidence so far
- Registered trials
- 151
- With posted results
- 16
- Published papers
- 2
Of 12 decided analyses: 0 favor sglt2 inhibitors, 12 find no difference, 0 favor the comparator.
Papers
- Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis.Meta-analysis / systematic review · 2025
- Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus.Trial report · 2021
Trials
- A Phase III Randomised, Double-blind Trial to Evaluate the Effect of 12 Weeks Treatment of Once Daily EMPagliflozin 10 mg Compared With Placebo on ExeRcise Ability and Heart Failure Symptoms, In Patients With Chronic HeArt FaiLure With Reduced Ejection Fraction (HFrEF) (EMPERIAL-reduced)NCT03448419 · 2 posted results
- International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Preserved Ejection FractionNCT03877224 · 2 posted results
- International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Reduced Ejection FractionNCT03877237 · 2 posted results
- A Phase III Randomised, Double-blind Trial to Evaluate the Effect of 12 Weeks Treatment of Once Daily EMPagliflozin 10 mg Compared With Placebo on ExeRcise Ability and Heart Failure Symptoms, In Patients With Chronic HeArt FaiLure With Preserved Ejection Fraction (HFpEF) (EMPERIAL - Preserved)NCT03448406 · 1 posted result
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and SitagliptinNCT02036515 · 5 posted results
- A Randomised, Double-blind, Placebo-controlled, Parallel Group, 52 Weeks Phase IV Trial to Evaluate Efficacy and Safety of Oral, Once Daily Empagliflozin in Elderly Japanese Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic ControlNCT04531462 · 1 posted result
- A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKDNCT07547878
- Semaglutide And Empagliflozin Combination Therapy Added To Automated Insulin Delivery In Adults With Type 1 Diabetes (SEMPA)NCT06894784